The Latest Cardiac and Vascular News
BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) […]
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical […]
Real-world data from 47 U.S. health systems shows three-year survival of 76% among systolic heart failure patients prescribed four GDMT classes, versus 52% among those prescribed none ALISO VIEJO, Calif., Oct. 21, 2026 /PRNewswire/ — egnite, Inc., a technology company advancing…
MIAMI, Oct. 21, 2026 /PRNewswire/ — Resolve Therapeutics, LLC, a clinical-stage biotechnology company developing nuclease-Fc fusion proteins designed to degrade pathogenic extracellular nucleic acids, today announced two e-posters featuring preclinical data on its RNase-Fc fusion protein…
VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium today announced the first site activation and first patient enrollment in the Globe Registry: Globe® Pulsed Field System Registry for Treating Patients with Symptomatic Atrial Fibrillation. The registry marks an important milestone in the continued commercial adoption of the Globe System following positive physician experience, strong procedural outcomes, and a growing body of evidence supporting the system’s unique integrated mapping and ab
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in
BOSTON–(BUSINESS WIRE)– #510k–Elucid has received FDA 510(k) clearance of FFR-IQ™, its software for noninvasive estimation of fractional flow reserve from coronary CT angiography.
SAN DIEGO–(BUSINESS WIRE)– #Medtech–Vektor Medical, a medical technology company advancing the treatment of cardiac arrhythmias through its non-invasive, AI-based arrhythmia analysis technology, vMap®, today announced the completion of patient enrollment in its IMPRoVED-AF randomized clinical study and the appointment of Brandon Allen as Senior Vice President of Sales. Together, these milestones mark important progress in Vektor’s efforts to expand commercial adoption of vMap and strengthen the clinica
SUNNYVALE, Calif.–(BUSINESS WIRE)–EBR Systems, Inc., developer of the world’s only left ventricular endocardial pacing (LVEP) system for heart failure, announces the appointment of Robert C. Canby, MD, as Chief Medical Officer. Key Highlights Robert Canby, MD, appointed Chief Medical Officer is a board-certified cardiac electrophysiologist who brings extensive experience across clinical practice, physician education, cardiovascular research, and medical device innovation. Dr. Canby practices
Financing Strengthens Balance Sheet and Supports Continued Product Innovation and Commercial GrowthWEST JORDAN, Utah, Oct. 20, 2026 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced that it has entered into a $100 million senior secured debt facility with Trinity Capital Inc., a leading provider of flexible capital solutions for innovative, growth-stage to lower middle market companies across the United States and Europe. Route 92 Medical has developed an integrated neurovascular platform that combines access, delivery, and control in a cohesive system, enabling clinicians to reach treatment sites reliably and efficiently. Tenzing® delivery catheters are foundational to the Route 92 platform, enabling atraumatic, precise, and controlled navigation through complex neurovascular anatomy. All Route 92 access and aspiration catheters are powered by custom-sized Tenzing delivery catheters and are size-matched to the vessels they access. Route 92 has also developed Monopoint®, the only mono-axial neurovascular platform, featuring a streamlined telescoping design that advances from a single point of control to simplify neurovascular intervention. “Entering into this financing with Trinity Capital is an important step for Route 92 as we execute on our growth strategy,” said Raj Denhoy, Chief Financial Officer of Route 92 Medical. “This facility gives us additional financial flexibility to support the strong demand we are seeing for our products. Trinity’s understanding of the medical technology sector and their confidence in our technology, commercial momentum, and long-term vision make them a valuable partner as we work to transform the treatment of neurovascular disease.” Route 92’s portfolio of advanced neurovascular catheters includes the FreeClimb® 46, 54, 70, and 88 systems, as well as the HiPoint® 70 and 88 systems, which feature Monopoint. HiPoint 88 is the first super-bore aspiration system with FDA clearance for direct aspiration of large vessel occlusions (LVOs) in acute ischemic stroke. The most recent addition, FreeClimb 46 with Tenzing 4, offers a differentiated tool for navigating more distal and smaller anatomies. Route 92’s catheters and systems are covered by a portfolio of more than 200 issued patents in the U.S. and international jurisdictions. About Route 92 Medical, Inc.Route 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering, innovative product design, and revolutionary procedural change. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn. CONTACT: Contacts:
For media:
Gwen Gordon
Gwen@gwengordonpr.com
